A phase I study of the GM-CSF antagonist E21R.
Olver IN, Hercus T, Lopez A, Vadas M, Somogyi AA, Doyle I, Foster DJ, Keefe D, Taylor A, Brown M, To LB, Cole J, Rawling T, Cambareri B, Myers M, Olszewski N, Bastiras S, Senn C, Hey A, Verma M, Wigley P.
Olver IN, et al. Among authors: bastiras s.
Cancer Chemother Pharmacol. 2002 Sep;50(3):171-8. doi: 10.1007/s00280-002-0474-y. Epub 2002 Jul 3.
Cancer Chemother Pharmacol. 2002.
PMID: 12203098
Clinical Trial.